₄Cheol Hyeon Kim

Summary for 2006 [at-glance overview of Cheol Hyeon Kim work for the selected year as suggested by data mining algorithms]

This is an Authoratory overview of author Cheol Hyeon Kim. According to available data, in 2006 Cheol Hyeon Kim published at least 4 articles. This work was completed in collaboration with several authors including Lee, Jae Cheol and Lee, Mi-Kyung. Many other authors have collaborated with Cheol Hyeon Kim as well. There is no information about the funding or the grants awarded to support this work.

Analysis of the article abstracts and the titles suggests that Cheol Hyeon Kim professional interests are focused around "lung cancer cells", "human lung cancer" and "4-chlorophenyl 4-methoxyphenyl 3-trifluoromethylpyrazole". These might also be referred to as "lung cancer", "cancer cells" or "fhit expression". Statistical analysis shows that Cheol Hyeon Kim's writing is likely to contains terms "cells", "lung", "cancer", "apoptosis", "fhit" and "growth".

The majority of Cheol Hyeon Kim articles are affiliated with Department of Internal Medicine, Korea Cancer Center Hospital, 215-4, Gongneung-dong, Nowon-gu, Seoul, 139-706, Republic of Korea. Luckily, one email address is on file.

EN FR ES RU

Inaccurate information, needs improvement

make correction leave comment ask question

Images [images we found on the Internet for Cheol Hyeon Kim]

Do you know Cheol Hyeon Kim who matches the profile above? Click the photo and let us know!

Alternative names (1) [other authors with names similar to Cheol Hyeon Kim]

₁₈₆Kim, C H

Year 2006 Charts [Cheol Hyeon Kim frequent coauthors and the most common unique vocabulary terms for the selected year]

Historical Performance Charts [graphical overview of Cheol Hyeon Kim publication and funding history for the range of years]

Emails (1) [email addresses extracted from Cheol Hyeon Kim affiliations]

hidden to prevent spam, click here to reveal

Cheol Hyeon Kim Coauthors (16) [all coauthors with the number of joint publications]

2

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

Affiliations (2) [condensed summary of the Cheol Hyeon Kim affiliations, the leading number and the color conveys importance]

₃Department of Internal Medicine, Korea Cancer Center Hospital, 215-4, Gongneung-dong, Nowon-gu, Seoul, 139-706, Republic of Korea.
₁Research Institute, National Cancer Center, 809 Madu-Dong, Ilsan-gu, Goyang, Gyeonggi, Korea,

Key Opinion Leader In [Cheol Hyeon Kim is considered a key opinion leader in any keyword where the rank of 5 is achieved, the leading number before the keyword shows the author's rank as compared to all other authors]

no keywords assigned

Keywords (32) [keywords assigned to Cheol Hyeon Kim articles by PubMed, the leading number and the color conveys importance]

₃Humans | ₃Lung Neoplasms | ₂Male | ₁Apoptosis | ₁Caspase 7 | ₁Neoplasms, Multiple Primary | ₁Quinazolines | ₁Signal Transduction | ₁Carcinoma, Non-Small-Cell Lung | ₁Tumor Cells, Cultured | ₁Tumor Markers, Biological | ₁Carboplatin | ₁Carcinoma, Squamous Cell | ₁Proto-Oncogene Proteins c-bcl-2 | ₁Acid Anhydride Hydrolases | ₁RNA, Small Interfering | ₁Antineoplastic Agents, Phytogenic | ₁Exons | ₁Middle Aged | ₁Neoplasm Proteins | ₁Caspase 3 | ₁Caspase 8 | ₁Choroid Neoplasms | ₁Antineoplastic Combined Chemotherapy Protocols | ₁Transfection | ₁Caspases | ₁Gene Deletion | ₁Paclitaxel | ₁Adenocarcinoma, Bronchiolo-Alveolar | ₁Plasmids | ₁Aged | ₁Carcinoma, Small Cell

Cheol Hyeon Kim Unique Vocabulary (96) [single words, word pairs and phrases obtained by analysis of abstracts and titles, the leading number and the color conveys importance; Cheol Hyeon Kim might be a good expert witness on these terms]

₁₈cells | ₁₇lung | ₁₄cancer | ₁₁apoptosis | ₁₁fhit | ₁₀growth | ₁₀sc-560 | ₇expression | ₇cell | ₆human | ₆treatment | ₅paclitaxel-induced | ₄sirna | ₄bac | ₄manner | ₄response | ₄synchronous | ₄results | ₄carcinoma | ₄induction | ₄fhit-expressing | ₄different | ₃gefitinib | ₃activation | ₃caspase | ₃4-methoxyphenyl | ₃chemotherapy | ₃reactive | ₃mutations | ₃oxygen | ₃squamous | ₃paclitaxel
₁₃lung cancer | ₉cancer cells | ₆fhit expression | ₄cell carcinoma | ₄human lung | ₄paclitaxel-induced apoptosis | ₄fhit-expressing cells | ₃control vector-transfected | ₃4-chlorophenyl 4-methoxyphenyl | ₃apoptosis lung | ₃vector-transfected cells | ₃squamous cell | ₃reactive oxygen | ₃4-methoxyphenyl 3-trifluoromethylpyrazole | ₃sirna treatment | ₂protein enhances | ₂caspase activation | ₂cells 4-chlorophenyl | ₂oxygen species-dependent | ₂growth suppression | ₂left lung | ₂suppress human | ₂cancer growth | ₂multiple primary | ₂celecoxib sc-560 | ₂synchronous multiple | ₂cancers different | ₂fhit protein | ₂enhances paclitaxel-induced | ₂different response | ₂primary lung | ₂3-trifluoromethylpyrazole acts
₈lung cancer cells | ₄human lung cancer | ₃4-chlorophenyl 4-methoxyphenyl 3-trifluoromethylpyrazole | ₃paclitaxel-induced apoptosis lung | ₃squamous cell carcinoma | ₃control vector-transfected cells | ₃apoptosis lung cancer | ₂reactive oxygen species-dependent | ₂cancer cells 4-chlorophenyl | ₂synchronous multiple primary | ₂suppress human lung | ₂lung cancers different | ₂protein enhances paclitaxel-induced | ₂3-trifluoromethylpyrazole acts reactive | ₂effect fhit expression | ₂manner suppress human | ₂multiple primary lung | ₂species-dependent manner suppress | ₂enhances paclitaxel-induced apoptosis | ₂fhit protein enhances | ₂lung cancer growth | ₂cells 4-chlorophenyl 4-methoxyphenyl | ₂different response gefitinib | ₂4-methoxyphenyl 3-trifluoromethylpyrazole acts | ₂oxygen species-dependent manner | ₂cancers different response | ₂acts reactive oxygen | ₂primary lung cancers | ₁fragile histidine triad | ₁caspase activation methods | ₁cells paclitaxel enhanced | ₁breast cancer cells

Reader's Comments (0) [comments posted by readers of Cheol Hyeon Kim profile]